

## antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
chloroquine and derivatives	15 studies <sup>1</sup>	-	-	0.71 [0.25 ; 2.02], 3 RCTs, I2=0% inconclusive result	-
ivermectin	4 studies <sup>2</sup>	-	-	0.71 [0.04 ; 11.32], 2 RCTs, I2=0% inconclusive result	-
bromhexine	1 study <sup>3</sup>	-	-	1.00 [0.02 ; 52.45], 1 RCT, I2=0% inconclusive result	-
nirmatrelvir / ritonavir (Paxlovid)	1 study <sup>4</sup>	-	-	-	-

### Notes

<sup>1</sup>Abella, 2020 (NCT04329923); EPICOS (Polo), 2022 (); HERO-HCQ (Naggie), 2021 (NCT04334148); Rojas-Serrano, 2021 (NCT04318015); Seet (HCQ), 2021 (NCT04446104); Syed, 2021 (NCT04359537); Barnabas RV, 2020 (NCT04328961); BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 (NCT04304053); COVID PREP HCQ (2x week, Rajasingham), 2020 (NCT04328467); COVID-PEP-Post exposure (Boulware), 2020 (NCT04308668); Grau-Pujol, 2020 (NCT04331834); PATCH-cohort 3 PreP (Abella), 2020 (NCT04329923); Gendelman, 2020 (); Rentsch, 2020 (); EPI-PHARE, 0 ()

<sup>2</sup>Ivercar-Tuc, 2021 (NCT04701710); Seet 2021, 2021 (NCT04446104); NCT04422561 (Shouman), 2020 (NCT04422561); Behera, 2020 ()

<sup>3</sup>Mikhaylov, 2021 (NCT04405999)

<sup>4</sup>EPIC PEP, 2022 (NCT05047601)